AQST - Aquestive Therapeutics provides business update and 2021 plans

Aquestive Therapeutics (AQST) provides business update:The company resubmitted a revised weight-based dosing regimen along with modeling and simulations for its seizure treatment Libervant in December 2020. Expects to resubmit the marketing application to the FDA during the first half of 2021.Aquestive plans on commencing another trial for its oral epinephrine treatment AQST-108 in Q1 of 2021.The company also aims to focus on growing its commercial sales of seizure treatment Sympazan and continuing to manufacture opioid addiction treatment Suboxone and other licensed products.Aquestive shares up 3.6% premarket.

For further details see:

Aquestive Therapeutics provides business update and 2021 plans